Bifidobacterium longum subsp. infantis.
The strain that matters.

The past several decades have seen an increase in the number of infants with gut dysbiosis. During this same time period, there has been a concomitant increase in the incidence of eczema, allergies, obesity, and diabetes.1-3 Research indicates these two events may be related—and improving the gut microbiome can make an impact.

But can the infant gut microbiome be restored to its original, natural state?

With Evivo activated B. infantis EVC001, Actibif®, yes it can.

A diagram of gut dysbiosis showing how Bifidobacterium longum subsp. infantis thrives in the infant gut.

The Right Strain

Research on the gut microbiome has led to the discovery of hundreds of species of bacteria. The species Bifidobacterium is one of the most important when it comes to the infant gut microbiome, and multiple Bifidobacterium subspecies exist—but only Bifidobacterium longum subsp. infantis (or B. infantis) has specifically co-evolved with human breast milk to thrive in the infant gut. Evivo was developed by scientists who were instrumental in identifying the symbiotic relationship between B. infantis and infants.

Isolated from a healthy infant, B. infantis EVC001 is activated to express the genes required to consume human milk oligosaccharides (HMOs). This well-studied strain was then developed based on scientific understanding of how B. infantis and HMOs should interact in the infant gut. Using a unique patented method during fermentation ensures that EvivoActivated B. infantis EVC001, Actibif® can work with breast milk better than any other strain of bacteria. 

Only Bifidobacterium longum subsp. infantis has specifically co-evolved with human breast milk to thrive in the infant gut.

The Right Food 

There are hundreds of HMOs found in breast milk, all of which are consumed by Bifidobacterium longum subsp. infantis in the infant gut. B. infantis is the only bacterium that possesses the enzymes necessary to break down the chemical bonds in HMOs. This gives B. infantis an advantage in the gut microbiome, providing it the ability to grow and outcompete other organisms.

Evivo is activated, which means it is better able to metabolize HMOs in breast milk, consuming them in a superior manner. The unique relationship between Evivo and HMOs then allows Bifidobacterium longum subsp. infantis to grow and dominate the infant gut.

The Right Time

The infant gut microbiome develops rapidly during the first year of life, beginning with inoculation of bacteria in the first moments after birth, and the gradual colonization of bacteria during the first weeks of life.4

Evivo, in combination with HMOs, is clinically proven to restore the infant gut microbiome to its original, natural state, setting infants up for improved health. Feeding Evivo with breast milk during the first 0–6 months of life is a key component to establishing a healthy infant gut microbiome—setting a foundation for lifelong health.


1. Vatanen T, Kostic AD, d’Hennezel E et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell. 2016;165(4):842-853.
2. Kalliomäki M, Collado MC, Salminen S, Isolauri E. Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr. 2008;87(3)534-538.
3. Fujimura KE, Sitarik AR, Havstad S et al. Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation. Nat Med. 2016;22(10):1187-1191.
4. Palmer C, Bik EM, DiGiulio DB et al. Development of the human infant intestinal microbiota. PLoS Biol. 2007;5(7):e177.